[Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].Clin Calcium. 2007 Jan; 17(1):88-92.CC
Abstract
Calcimimetics drug such as cinacalcet suppress the secretion of parathyroid hormone by sensitizing parathyroid calcium receptors to extracellular ionized calcium. Standard treatment for secondary hyperparathyroidism is associated with the risk of hypercalcemia, but cinacalcet don't induce elevation of serum calcium. And some studies were reported the use of cinacalcet not only to manage primary hyperparathyroidism, but also secondary hyperparathyroidism in nondialyzed stage, renal transplant patients and parathyroid carcinoma.
MeSH
Pub Type(s)
Journal Article
Review
Language
jpn
PubMed ID
17211098
Citation
Nakanishi, Shohei, and Masafumi Fukagawa. "[Therapeutic Agents for Disorders of Bone and Calcium Metabolism. the Calcimimetic Cinacalcet HCl]." Clinical Calcium, vol. 17, no. 1, 2007, pp. 88-92.
Nakanishi S, Fukagawa M. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl]. Clin Calcium. 2007;17(1):88-92.
Nakanishi, S., & Fukagawa, M. (2007). [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl]. Clinical Calcium, 17(1), 88-92.
Nakanishi S, Fukagawa M. [Therapeutic Agents for Disorders of Bone and Calcium Metabolism. the Calcimimetic Cinacalcet HCl]. Clin Calcium. 2007;17(1):88-92. PubMed PMID: 17211098.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].
AU - Nakanishi,Shohei,
AU - Fukagawa,Masafumi,
PY - 2007/1/11/pubmed
PY - 2007/3/24/medline
PY - 2007/1/11/entrez
SP - 88
EP - 92
JF - Clinical calcium
JO - Clin Calcium
VL - 17
IS - 1
N2 - Calcimimetics drug such as cinacalcet suppress the secretion of parathyroid hormone by sensitizing parathyroid calcium receptors to extracellular ionized calcium. Standard treatment for secondary hyperparathyroidism is associated with the risk of hypercalcemia, but cinacalcet don't induce elevation of serum calcium. And some studies were reported the use of cinacalcet not only to manage primary hyperparathyroidism, but also secondary hyperparathyroidism in nondialyzed stage, renal transplant patients and parathyroid carcinoma.
SN - 0917-5857
UR - https://wwww.unboundmedicine.com/medline/citation/17211098/[Therapeutic_agents_for_disorders_of_bone_and_calcium_metabolism__The_calcimimetic_cinacalcet_HCl]_
DB - PRIME
DP - Unbound Medicine
ER -